DCPH Deciphera Pharmaceuticals Inc.

26.21
+0.78  (+3%)
Previous Close 25.43
Open 25
Price To Book 3.19
Market Cap 987100078
Shares 37,661,201
Volume 145,491
Short Ratio
Av. Daily Volume 323,383

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168152
  2. 8-K - Current report 181168148
  3. 8-K - Current report 181130577
  4. EFFECT - Notice of Effectiveness 181121192
  5. CORRESP [Cover] - Correspondence

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 update due YE 2018.
DCC-3014
Solid tumors or hematological malignancies
Phase 3 completion of enrolment announced November 15, 2018. Data due mid-2019.
DCC-2618 - INVICTUS
Gastrointestinal Stromal Tumors (GIST) - fourth-line
Phase 1 update at ESMO October 2018. ORR 21%, PFS 40 weeks - 2nd/3rd line.
DCC-2618
Gastrointestinal Stromal Tumors (GIST)
Phase 1 expansion data due 2019.
DCC-2618
Gastrointestinal Stromal Tumors (GIST)
Phase 3 trial to be initiated 4Q 2018.
DCC-2618
Gastrointestinal Stromal Tumors (GIST) - second-line
Phase 1b trial complete.
Rebastinib
Breast Cancer
Phase 1b/2 trial initiation announced October 23, 2018.
Rebastinib
Solid tumors

Latest News

  1. Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference
  2. Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors
  3. Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results
  4. Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors
  5. Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress
  6. Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference
  7. Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer
  8. Why Raymond James Is Bullish On Deciphera, Dova Pharmaceuticals
  9. Deciphera Pharmaceuticals, Inc. to Participate in Citi’s 13th Annual Biotech Conference
  10. Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results
  11. Deciphera Pharmaceuticals, Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference
  12. 3 Top Stocks That Aren't on Wall Street's Radar
  13. Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
  14. Deciphera Pharma Hit With Sell-Side Downgrade On Valuation After 50% Gain
  15. Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities 2018 Life Sciences Conference
  16. Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate
  17. Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168152
  2. 8-K - Current report 181168148
  3. 8-K - Current report 181130577
  4. EFFECT - Notice of Effectiveness 181121192
  5. CORRESP [Cover] - Correspondence
  6. UPLOAD [Cover] - SEC-generated letter
  7. S-3 - Registration statement under Securities Act of 1933 181097841
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998315
  9. 8-K - Current report 18998091
  10. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 18912036